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The efficacy and safety of a single tablet regimen (STR) of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/
F/TDF) were analyzed in Phase 3 clinical trials in antiretroviral therapy (ART)-naïve and ART-experienced Asian subjects infect-
ed with human immunodeficiency virus (HIV)-1. Studies GS-US-236-102 and GS-US-236-103 were randomized, double-blind, 
placebo-controlled, 144-week studies conducted in ART-naïve subjects, comparing E/C/F/TDF versus efavirenz (EFV)/F/TDF or 
ritonavir-boosted atazanavir (ATV+RTV) plus emtricitabine/tenofovir DF (F/TDF), respectively. Studies GS-US-236-115 and GS-
US-236-121 were randomized, open-label, 96-week long conducted in ART-experienced subjects, who switched to E/C/F/TDF 
from ritonavir-boosted protease inhibitors (PI+RTV)+F/TDF, or non-nucleoside reverse transcriptase inhibitors (NNRTI)+F/TDF 
regimens. The E/C/F/TDF appeared to have sustained efficacy and safety and was well tolerated in the small number of ART-
naïve and ART-experienced Asian subjects.. 
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The single tablet regimen (STR) containing elvitegravir, co-
bicistat,  emtricitabine  and tenofovir disoproxil fumarate (E/
C/F/TDF) is a recommended regimen in the guidelines of the 
US Department of Health and Human Services and the Euro-
pean acquired immunodeficiency syndrome (AIDS) Clinical 
Society [1, 2]. In two Phase 3 randomized, double-blind, pla-
cebo-controlled clinical trials in ART-naïve adults infected 
with the human immunodeficiency virus (HIV)-1, E/C/F/TDF 
(n = 701) demonstrated non-inferior efficacy at week 48, 96, 
and 144 compared to the STR of efavirenz (EFV)/F/TDF (GS-
US-236-0102, Study 102) and the ritonavir-boosted atazanavir 
(ATV+RTV) plus emtricitabine/tenofovir DF (F/TDF, GS-
US-236-0103, Study 103) as well as favorable safety and toler-
ability [3-9]. Studies GS-US-236-115 (STRATEGY-PI) and GS-
US-236-121 (STRATEGY-NNRTI) examined the efficacy, 
safety, and tolerability of switching to E/C/F/TDF from ritona-
vir-boosted protease inhibitors (PI+RTV)+ F/TDF or non-nu-
cleoside reverse transcriptase inhibitors (NNRTI)+F/TDF reg-
imens, respectively, in virologically suppressed (HIV-1 RNA 
<50 copies/mL), ART-experienced adult subjects [10-13]. At 
week 48 and 96, the STRATEGY-PI study showed that switch-
ing to E/C/F/TDF from a PI+RTV-based regimen was associ-
ated with significantly higher rates of virological success, low-
er triglyceride levels, and improvements in self-reported 
diarrhea and bloating [14]. The STRATEGY-NNRTI study 
showed the non-inferior efficacy of E/C/F/TDF versus re-
Table 1. Baseline characteristics: Asian subpopulation studies 
Characteristic, % (n)
ART-naïve Studies 102 and 103
E/C/F/TDF
(n=23)
EFV/F/TDF
(n=10)
ATV+RTV+F/TDF
(n=17)
Median Age, years (range) 33 (19-48) 32 (25-49) 35 (19-52)
Male 83 (19) 90 (9) 88 (15)
Asymptomatic HIV Infection 87 (20) 100 (10) 82 (14)
HBV : HCV Seropositive 0%:0% 10%: 0% 12%: 0%
Country of Enrollment
   USA 35 (8) 100 (10) 18 (3)
   Thailand 30 (7) 0 24 (4)
   Europe 26 (6) 0 6 (1)
   Othera 9 (2) 0 53 (9)
Median HIV-1 RNA, log10c/mL 4.8 4.6 4.6
   > 100,000 c/mL 35 (8) 30 (3) 24 (4)
Mean CD4+ T cell count, cells/mm3, (range) 374  (220-570) 338 (152-653) 346 (51-507)
   ≤350 52 (12) 60 (6) 47 (8)
   ≤200 0 20 (2) 12 (2)
Median GFR by Cockcroft Gault, mL/min 100 93 105
Characteristics, % (n)
ART-experienced Studies 115 and 121
STRATEGY-PI STRATEGY-NNRTI
E/C/F/TDF
(n =7)
PI+RTV+ TVD
(n =2)
E/C/F/TDF
(n =4)
NNRTI+TVD
(n =9)
Median Age, years (range) 33 (22-45) 48 (40-55) 45 (40-51) 38 (26-50)
Male 71 (5) 100 (2) 100 (4) 100 (9)
Asymptomatic HIV Infection 54 (4) 100 (2) 25 (1) 67 (6)
HBV : HCV Seropositive , n 0 : 0 0 : 1 0 : 0 1 : 0
Country of Enrollment
   USA 14 (1) 50 (1) 100 (4) 78 (7)
   Europe 71 (5) 50 (1) 0 11 (1)
   Otherb 14 (1) 0 0 11 (1)
Mean CD4+ T cell count, cells/mm3, (range) 548 (327-996) 478 (385-570) 402 (210-805) 592 (300-927)
   ≤350 14 (1) 0 75 (3) 22 (2)
   ≤200 0 0 25 (1) 0
Median GFR by Cockcroft Gault, mL/min 104 104 125 112
aOther: E/C/F/TDF; Australia (2); ATV+RTV+TVD; Australia (7); Canada (2). 
bOther: E/C/F/TDF: Switzerland (1); NNRTI+TVD: Australia (1).
E, elvitegravir; C, cobicistat; F, emtricitabine; TDF, tenofovir disoproxil fumarate; EFV, efavirenz; ATV, atazanavir; RTV, ritonavir; PI, protease inhibitor; NNRTI, non-nucleoside 
reverse transcriptase inhibitor; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; GFR, glomerular filtration rate.
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maining on the NNRTI+ F/TDF regimen, improvement in pa-
tient-reported outcomes (PROs) related to NNRTI-associated 
neuropsychiatric side effects, and greater treatment satisfac-
tion scores [15]. There is limited data on the efficacy and safe-
ty of current antiretroviral therapies in Asian subjects infected 
with HIV-1. Here, we report a sub-analysis of E/C/F/TDF effi-
cacy and safety data in Asian subjects enrolled in Studies 102 
and 103 at week 144 as well as Studies 115 and 121 at week 96.
In the two ART-naïve studies, 1,408 subjects (E/C/F/TDF, n 
= 701 vs. EFV/FTC/TDF, n = 352 vs. ATV+RTV+ F/TDF, n = 
355) were enrolled and received at least one dose of a study 
drug. In the two studies with ART-experienced, virologically 
suppressed subjects, 867 (Study 115: E/C/F/TDF, n = 293 vs. 
PI+RTV+ F/TDF, n = 140 and Study 121: E/C/F/TDF, n = 291 
vs. NNRTI+ F/TDF, n=143) were enrolled and received at least 
one dose of a study drug. In these four clinical trials, 72 Asian 
subjects consisting of 50 ART-naïve (E/C/F/TDF, n=23; EFV/
F/TDF, n = 10; and ATV+RTV+ F/TDF, n = 17) and 22 ART-ex-
perienced, virologically suppressed (Study 115: E/C/F/TDF, n 
= 7 and PI+RTV+ F/TDF, n=2; and Study 121: E/C/F/TDF and 
n = 4; NNRTI+ F/TDF, n = 9) were included in this sub-analysis 
of the E/C/F/TDF data [16]. 
The baseline demographics and disease characteristics of 
the ART-naïve (Studies 102 and 103, pooled) and ART-experi-
enced (Study 115 and Study 121, separately) subjects on E/C/
F/TDF were as follows: median age 33, 33, and 45 years; male: 
83%, 71%, and 100%; mean CD4 count: 374, 548, and 402 
cells/mm3; and median estimated glomerular filtration rate 
(eGFR) using the Cockcroft-Gault method: 100, 104, and 125 
mL/min, respectively (Table 1).
Similar high rates of virological success (HIV-RNA <50 cop-
ies/mL, FDA Snapshot Analysis) and comparable immuno-
logical outcomes were observed in the ART-naïve and ART-ex-
perienced subjects on E/C/F/TDF. In the ART-naïve subjects, 
the virological success (HIV-1 RNA <50 copies/mL) was 91, 
80, and 76% with E/C/F/TDF, EFV/F/TDF, ATV+RTV+ F/TDF, 
respectively at week 144. The mean CD4+ T cell count (/mm3) 
increased from baseline through week 144 (235, E/C/F/TDF; 
161, EFV/F/TDF; and 250, ATV+RTV+ F/TDF). In the ART-ex-
perienced, virologically suppressed subjects, the virological 
success (maintenance of HIV-1 RNA <50 copies/mL) of the E/
C/F/TDF regimen was 86 and 100% (Studies 115 and 121, re-
spectively) at week 96. The virological success rates for sub-
jects who remained on the PI+RTV+ F/TDF or NNRTI+ F/TDF 
regimens were 100 and 67%, respectively, both at week 96. The 
mean CD4+ T cell count increases were similar for E/C/F/
TDF in both Studies 115 and 121: 61 and 71 cells/mm3 com-
pared to -30 and 162 cells/mm3 for patients who remained on 
the PI+RTV+ F/TDF and NNRTI+ F/TDF regimens, respec-
tively (Fig. 1).
The overall safety and tolerability of E/C/F/TDF in both 
ART-naïve and ART-experienced subjects were similar to that 
of E/C/F/TDF in the overall populations enrolled in the four 
studies. In the ART naïve subjects, the most common study 
drug-related adverse events (AEs) with E/C/F/TDF were nau-
sea (n = 4 vs. EFV/F/TDF, n = 0 and ATV+RTV+ F/TDF, n = 5), 
abnormal dreams (n = 2 vs. 5 and 1, respectively), diarrhea (n 
= 2 vs. 0 and 3, respectively) and dizziness (n = 1 vs. 2 and 2, 
respectively). Grade 3AEs occurred in subjects with similar 
frequency between E/C/F/TDF (17%, n = 4) and EFV/F/TDF 
(20%, n = 2) while no subjects in the ATV+RTV+ F/TDF treat-
ment arm experienced this Grade. Furthermore, there were 
no Grade 4 AEs. There were few study drug discontinuations 
due to AEs in the ART-naïve subjects and the frequency was 
similar between the treatment arms [E/C/F/TDF, n = 1 due to 
Figure 1. Virological and immunological outcomes studies 102 and 103: 
Asian subset through week 144. 
HIV, human immunodeficiency virus; RNA, ribonucleic acid; FDA, food and drug 
administration; E, elvitegravir; C, cobicistat; F, emtricitabine; TDF, tenofovir diso-
proxil fumarate; EFV, efavirenz; FTC, emtricitabine; ATV, atazanavir; RTV, ritonavir; 
TVD, truvada; PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase 
inhibitor
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lymphoma; EFV/F/TDF, n=1 due to presyncope; and AT-
V+RTV+ F/TDF, n = 2 due to gastrointestinal disorder consist-
ing of diarrhea (one subject) and nausea, vomiting, and flatu-
lence (one subject,  who also had dizziness)].  In the 
ART-experienced subjects, the most common study drug-re-
lated AEs with E/C/F/TDF in Study 115 were, enlarged parotid 
gland and alopecia (n = 1 each) and in Study 121, increased 
weight (n = 1) and GFR (n = 1 in male, 47 years old, observed 
as Grade 1). Only one Grade 3-4 AE occurred in the ART-ex-
perienced subjects, which was a subject with a clavicle frac-
ture treated on E/C/F/TDF. There were no subjects on E/C/F/
TDF in the ART-experienced studies that discontinued the 
study drug because of AEs and no subjects in either the ART-
naïve or ART-experienced discontinued E/C/F/TDF because 
of renal AEs. The treatment emergent Grade 3-4 laboratory 
abnormalities observed with E/C/F/TDF were all Grade 3 (al-
anine transaminase [ALT], n = 2; aspartate transaminase 
[AST], n = 1; and hyperuricemia, n = 1) in ART-experienced 
subjects.
Cobicistat induced a slight increase in serum creatinine 
(SCr) with a consequent reduction in the eGFR in Phase 1 and 
2 clinical trials [17-19]. The changes in SCr are caused by the 
inhibition of tubular creatinine secretion with no effect on the 
actual glomerular filtration rate, as measured by the clearance 
of iohexol [18]. In this sub-analysis in Asian subjects, the me-
dian changes from baseline in SCr were similar to that ob-
served in the overall study population on E/C/F/TDF. The me-
dian change from baseline in the SCr of the ART-naïve 
subjects was 0.14 mg/dL with E/C/F/TDF vs. -0.03 mg/dL 
with EFV/F/TDF and 0.04 mg/dL with ATV+RTV+F/TDF. Fur-
thermore, the values for the ART-experienced subjects were 
0.06 mg/dL with E/C/F/TDF vs. -0.18 mg/dL with PI+RTV+F/
TDF (Study 115) and 0.05 mg/dL with both E/C/F/TDF and 
NNRTI+F/TDF (Study 121).
In Asian subjects, the median changes from baseline in the 
fasting lipid parameters [total cholesterol (TC) and high-den-
sity lipoprotein (HDL)] were slight with E/C/F/TDF, which re-
sulted in minimal median changes in the TC:HDL ratio [ART-
naïve (0.1) and ART-experienced (Studies 115 and 121, 0.2 
and 0.0, respectively)] (Fig. 2)
A limitation of this sub-analysis is the small number of Asian 
subjects, who accounted for 4 and 3% of the overall popula-
tion of the participants enrolled in the ART-naïve and ART-ex-
perienced studies. This restricted the definitive assessment of 
the safety and tolerability of E/C/F/TDF in Asian subjects, and 
may limit generalization of the results.
In these sub-studies of Phase 3 clinical trials of E/C/F/TDF, 
the Asian subjects with HIV-1 infections who were either initi-
ating E/C/F/TDF therapy or switching to E/C/F/TDF from 
RTV-boosted PIs or NNRTIs (both combined with F/TDF) 
demonstrated a high (>90%) efficacy (HIV-1 RNA <50 copies/
mL). The safety and tolerability profile of E/C/F/TDF in the 
Asian subjects was similar to that of E/C/F/TDF in the overall 
study populations investigated [8, 9, 12, 13]. No new or unique 
safety concerns were observed in the ART-naïve and ART-ex-
perienced Asian subjects on E/C/F/TDF. The AEs leading to 
study drug discontinuation were uncommon with no renal 
AEs leading to discontinuation with E/C/F/TDF. Changes in 
the SCr of Asian subjects on E/C/F/TDF were consistent with 
those observed in the overall populations enrolled in the ART-
naïve and ART-experienced studies. The changes from base-
line in SCr observed at week 144 and 96 (ART-naïve and 
ART-experienced, respectively) were similar to those observed 
from baseline to week 48, which suggests the initial increase 
in SCr with E/C/F/TDF was caused by the inhibitory effect of 
cobicistat on the renal tubular creatinine secretion, which 
then stabilized [20]. The slight changes in the lipid parameters 
Figure 2. Median change in fasting lipids from baseline. 
TC, total cholesterol; LDL, low-density lipoprotein; TG, triglycerides; HDL, high-
density lipoprotein.
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in Asian subjects on E/C/F/TDF resulted in minimal changes 
in the TC:HDL ratio and were similar to those in the overall 
study population. In summary, from this sub-analysis in a 
small number of Asian subjects, E/C/F/TDF appears to have 
sustained efficacy and is safe and well-tolerated based on the 
available data in both the ART-naïve and ART-experienced 
Asian subjects.
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